Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Cutia Therapeutics's Revenue for the
six
months ended in Dec. 2025 was HK$298.1 Mil. Cutia Therapeutics's average Accounts Receivable for the
six
months ended in Dec. 2025 was HK$117.2 Mil.
Hence, Cutia Therapeutics's Receivables Turnover for the
six
months ended in Dec. 2025 was 2.54.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Cutia Therapeutics Receivables Turnover Related Terms
Cutia Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Cutia Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02487 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Cutia Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cutia Therapeutics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Cutia Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cutia Therapeutics (HKSE:02487) has a Receivables Turnover of 2.54 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cutia Therapeutics and its competitors. According to the industry distribution chart, Cutia Therapeutics ranks #629 out of 845 companies in the Biotechnology industry, placing it in the top 74.4%.
Is Cutia Therapeutics' Receivables Turnover too high?
Cutia Therapeutics' current Receivables Turnover is 2.54. The Biotechnology industry median Receivables Turnover is 5.22. Cutia Therapeutics' value of 2.54 is 51.3% below this industry median. Based on the distribution chart, Cutia Therapeutics ranks #629 out of 845 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cutia Therapeutics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cutia Therapeutics' Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cutia Therapeutics ranks #629 out of 845 companies for Receivables Turnover. This places Cutia Therapeutics in the lower half of its industry. The industry median Receivables Turnover is 5.22. Cutia Therapeutics' value of 2.54 is 51.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.22, based on 845 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cutia Therapeutics's current Receivables Turnover of 2.54 is 51.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cutia Therapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cutia Therapeutics's current Receivables Turnover is 2.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cutia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Cutia Therapeutics (HKSE:02487) is currently considered Possible Value Trap. The stock's GF Value™ is HK$17.00, compared to a current price of HK$2.19 — trading 87.1% below its estimated fair value. The current Receivables Turnover is 2.54 and 51.3% below the Biotechnology industry median of 5.22. Cutia Therapeutics' overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Cutia Therapeutics (HKSE:02487), the current Receivables Turnover is 2.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cutia Therapeutics (HKSE:02487) Overvalued in 2026?
Based on GuruFocus' analysis, Cutia Therapeutics stock appears to be undervalued.
The current stock price of HK$2.19 is trading 87.1% below its estimated GF Value™ of HK$17.00.
GuruFocus considers Cutia Therapeutics to be Possible Value Trap.
Key valuation signals for HKSE:02487:
Receivables Turnover: 2.54
GF Value™: HK$17.00 vs. price of HK$2.19 (87.1% below fair value)
Industry Position: 51.3% below the Biotechnology median (#629 of 845)
No single metric tells the full story. See the HKSE:02487 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cutia Therapeutics is an investment holding company. The Company and its subsidiaries are principally engaged in developing inventive and comprehensive solutions that are tailored to meet the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market. It has a proprietary CATAME technology platform, which includes: Colloidal-Emulsification-Active Encapsulation (CEAE) platform, Aerosol (ARS) platform, Transdermal Delivery (TDD) platform, Actives & Formulation Evaluation (AFE) platform, Micro/Nano-Particulates & Self-Assembly (MiSA) platform, and Ex vivo & Efficacy Evaluation (EVEE) platform. It enables the development of a wide range of product dosage forms and the relevant formulation technology.
40GF Score
Get the complete analysis for HKSE:02487
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02487 has been successfully added to your 
